中国TOPCon电池行业市场规模测算 逻辑模型 头豹词条报告系列 吴一凝 发布日期：2024/08/22 TOPCon电池行业规模 1. TOPCon电池累计规模 (结论图) P3 2. TOPCon电池累计规模 P4 3. 全球光伏发电装机容量 P5 4. TOPCon电池市场占比 P6 5. TOPCON电池设备成本 P7 6. 溯源信息链接引用 P8 7. 法律声明 P9 8. 头豹研究院简介 P10 9. 头豹词条介绍 P11 10. 头豹词条报告 P12 ሙ 1. TOPCon电池累计规模（结论图） 全球光伏发电装机容 B TOPCon电池累计 TOPCon电池市场占 规模 FF C 结论 = B*C*D TOPCON电池设备成 本 D | 3 2. TOPCon电池累计规模 P4 TOPCon电池累计规模:（结论=B*C*D）TOPCon电池累计规模:（结论=B*C*D） 年份 2020 2021 2022 2023 2024E 2025E 2026E 2027E 2028E 数据(亿元) 31.87 42.68 189.24 570.4 1,717.38 2,310 2,574 2,718.72 ...

Industry Overview - The Chinese traditional Chinese medicine (TCM) industry is experiencing high growth driven by the silver economy and supportive government policies [1] - TCM includes various forms such as medicinal materials, decoction pieces, and proprietary Chinese medicines, classified by efficacy, natural attributes, and dosage forms [5] - The TCM industry has a long development history, with milestones including policy support, scientific breakthroughs, and international recognition [7][8] Industry Scale and Market Dynamics - The TCM industry has shown significant growth, with sales increasing from 4,414 billion yuan in 2020 to 5,549.9 billion yuan in 2023, a 25.73% increase [11] - Leading TCM companies like Baiyunshan, Huarun Sanjiu, and Yunnan Baiyao have achieved annual revenues exceeding 10 billion yuan [12] - The national centralized procurement of TCM has led to an average price reduction of 49%, promoting industry upgrades and market reshuffling [22] Industry Chain Analysis - The TCM industry chain includes upstream suppliers of medicinal materials, midstream manufacturers of decoction pieces and proprietary medicines, and downstream sales channels and TCM medical institutions [15] - The Chinese medicinal materials market has grown from 1,368.8 billion yuan in 2013 to 1,911.56 billion yuan in 2022, with planting area expanding from 4,161.3 million mu in 2012 to 9,032.3 million mu in 2021 [18][19] - The number of TCM medical institutions increased from 60,738 in 2018 to 80,319 in 2022, driving demand for TCM products [26] Industry Trends - New TCM registration standards emphasize innovation, improvement, and integration with classical formulas, promoting industry development [30] - Adjustments to the national medical insurance and essential drug lists are expected to increase the inclusion of TCM products, driving market growth [33][36] - The aging population and the "One Belt, One Road" initiative are creating new opportunities for the TCM industry [28] Key Companies - Pien Tze Huang has shown strong financial performance, with revenue increasing from 5.72 billion yuan in 2019 to 10.06 billion yuan in 2023, and net profit rising from 1.64 billion yuan to 3.37 billion yuan [39][40] - Pien Tze Huang's core product, Pien Tze Huang, is a nationally protected TCM with significant market influence and international recognition [42] - The company has diversified its business into pharmaceuticals, cosmetics, and food, with pharmaceuticals accounting for over 85% of its revenue [44]

Investment Rating - The report rates the myasthenia gravis (MG) drug industry with a five-star rating, indicating a positive outlook for investment opportunities in this sector [29]. Core Insights - The myasthenia gravis drug industry is characterized by a market size growth from 1.125 billion RMB in 2018 to 1.233 billion RMB in 2023, with a compound annual growth rate (CAGR) of 1.84% [25]. - The industry is expected to continue growing, with projections indicating a market size increase to 1.342 billion RMB by 2028, maintaining a CAGR of 1.79% [25]. - The primary treatment options include cholinesterase inhibitors, corticosteroids, immunosuppressants, and targeted therapies, with the most common drug being pyridostigmine [6][7]. Industry Definition - The myasthenia gravis drug industry focuses on the research, development, and production of medications specifically targeting myasthenia gravis, an autoimmune disease characterized by impaired neuromuscular transmission [4][6]. Industry Classification - The industry can be classified into several categories based on drug types: - Cholinesterase inhibitors (e.g., pyridostigmine) - Corticosteroids (e.g., prednisone) - Immunosuppressants (e.g., azathioprine, mycophenolate mofetil) - Targeted therapies (e.g., monoclonal antibodies) [6][7]. Industry Characteristics - The industry features a low approval rate for targeted therapies, with only a few options available for clinical use [7]. - Drug usage rates among myasthenia gravis patients remain low, with only 40-50% of patients receiving treatment [8]. - High capital barriers exist due to the capital-intensive nature of drug development and the need for advanced technology and skilled personnel [9]. Development History - The industry has evolved through three main phases: - 1900-1949: Initial recognition and early drug treatments began. - 1950-2010: Significant advancements in understanding the disease and the introduction of various treatment options. - 2011-present: A period of innovation with the emergence of new therapies and inclusion of some drugs in national insurance coverage [10][11][12]. Industry Size - The market size for myasthenia gravis drugs has shown steady growth, with a historical increase from 1.125 billion RMB in 2018 to 1.233 billion RMB in 2023, and projected growth to 1.342 billion RMB by 2028 [25][26]. Competitive Landscape - The industry is structured into three tiers of companies: - First tier: Major players include Shanghai Pharmaceuticals, Roche, and AstraZeneca. - Second tier: Companies like Zhongxi Sanwei Pharmaceutical and Haizheng Pharmaceutical. - Third tier: Includes companies like Hengrui Medicine and Pude Pharmaceutical [39][40]. Policy Overview - Recent policies have focused on enhancing the management of rare diseases, including myasthenia gravis, and improving access to treatment through the establishment of a rare disease directory [31][32].

Industry Investment Rating - The report does not explicitly provide an investment rating for the display panel industry [1] Core Viewpoints - The report focuses on the Chinese display panel industry, particularly the upstream supply chain and key materials, highlighting the challenges and opportunities in domestic production and technological breakthroughs [1][2] - LCD panels dominate the market due to lower costs, while OLED panels face technical and material challenges, limiting their widespread adoption [5][6] - The upstream supply chain, including materials and equipment, is highly profitable, with foreign companies dominating key areas such as OLED organic materials and manufacturing equipment [9][20][26] Display Panel Classification - Display panels are categorized into non-self-emissive (mainly LCD) and self-emissive (OLED, Micro LED, etc) [5][6] - LCD panels, including TFT-LCD, QLED, and Mini LED, are mainstream due to their cost-effectiveness, despite being thicker and having limited viewing angles compared to OLED [6][7] - OLED panels offer advantages like high contrast, wide viewing angles, and flexibility but face challenges such as short blue light lifespan and complex production processes [6][7] LCD Cost Structure - LCD cost structure: color filters (20%), backlight modules (15%), polarizers (10%), and glass substrates (10%) account for 55% of total costs [2] - Raw materials make up 70% of LCD costs, with larger panel sizes increasing the cost of color filters and polarizers [2] - Companies with well-established upstream supply chains, such as AU Optronics, have higher gross margins due to better cost control [2] OLED Cost Structure - OLED cost structure: equipment (35%) and organic materials (23%) account for nearly 60% of total costs [3] - OLED equipment and organic materials are highly technical and dominated by Japanese, Korean, and American companies [3][20] - OLED organic materials, particularly terminal materials, have high technical barriers and are critical for panel performance and lifespan [3][20] Display Panel Industry Supply Chain - The display panel industry has a long supply chain, with upstream materials and equipment being highly profitable, while midstream panel manufacturing is highly competitive with lower margins [8][9] - Upstream materials like polarizers and glass substrates have high profit margins, with polarizers at around 40% and glass substrates at 50%-60% [10] - Foreign companies dominate the upstream supply chain, particularly in OLED organic materials and manufacturing equipment [20][26] Polarizers - Polarizers for OLED panels have higher technical barriers compared to LCD polarizers, with the market dominated by Japanese and Korean companies like Sumitomo Chemical and LG Chem [14][15] - Chinese companies like Sanritz and Shengbo have a small market share in TFT-LCD polarizers, indicating significant room for domestic growth [16] Electronic Glass - Electronic glass, including cover glass and display glass substrates, is dominated by foreign companies like Corning, with Chinese companies gradually entering the mid-to-high-end market [17][18][19] - Display glass substrates account for over 60% of the electronic glass market, while cover glass accounts for over 30% [18] OLED Organic Materials - OLED terminal materials are highly technical and dominated by Japanese, Korean, and American companies like Merck, UDC, and Doosan [20][21] - Chinese companies are mainly focused on upstream intermediates, with domestic OLED material localization rate at around 38% in 2023 [24] Manufacturing Equipment - Key OLED manufacturing equipment, such as TFT, evaporation, and encapsulation devices, is dominated by foreign companies, with limited domestic production [26][28] - Domestic equipment manufacturers have a presence in the module and testing stages but face challenges in core technology areas [28] Downstream Applications - LCD panels dominate large-size applications like TVs and commercial displays, while OLED is increasingly penetrating mid-range products in small-size applications like smartphones and wearables [11]

2024年 头豹行业词条报告 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度 机密性文件（在报告中另行标明出处者除外）。未经头豹研究院事先书面许可，任何人不得以 任何方式擅自复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的 行为发生，头豹研究院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有 商业活动均使用"头豹研究院"或"头豹"的商号、商标，头豹研究院无任何前述名称之外的 其他分支机构，也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 Copyright © 2024 头豹 Leadleo.com 企业竞争图谱：2024年废水处理ESG 头豹词条报告 系列 文上 · 头豹分析师 2024-08-09 未经平台授权，禁止转载 版权有问题？点此投诉 行业： 电力、热力、燃气及水生产和供应业/水的生产和供应业/污水处理及其再生利用/污水处理 综合性企业/综合企业 关键词： 污水处理 ESG 废水 | --- | --- | --- | --- | |-------------------------|----------------- ...

Investment Rating - The report does not explicitly state an investment rating for the liquid cooling fast charging industry Core Insights - The liquid cooling fast charging market in China is projected to grow significantly, with revenues expected to reach 578.84 billion RMB in 2024, up from 388.2 billion RMB in 2023, representing a growth rate of 49.11% [21][27] - The number of new energy vehicles (NEVs) in China is forecasted to increase from 2,041,000 in 2023 to 3,061,500 in 2024, indicating a growth rate of 50% [23][25] - The penetration rate of liquid cooling fast charging vehicles is expected to rise from 5.8% in 2023 to 6.96% in 2024, reflecting a growth rate of 20% [24][25] Market Size Overview - The annual revenue from liquid cooling fast charging in China has shown substantial growth, increasing from 2.67 billion RMB in 2018 to an estimated 261.32 billion RMB in 2024 [21][27] - The market size for liquid cooling fast charging equipment is projected to grow from 6.6 billion RMB in 2018 to 317.52 billion RMB in 2024 [21][34] Vehicle Ownership and Charging Infrastructure - The number of liquid cooling fast charging stations is expected to increase from 2 million in 2023 to 2.7 million in 2024, with a growth rate of 35% [30][34] - The average number of fast charging piles per station is projected to remain stable at 2 from 2023 to 2024, with a potential increase to 3 by 2025 [32][34] Charging Costs and Revenue - The average cost of liquid cooling fast charging piles is expected to decrease gradually from 60,000 RMB in 2023 to 54,240 RMB by 2028 [33][34] - The average daily charging amount for new energy vehicles is projected to decline slightly from 34.3 RMB in 2023 to 31 RMB by 2028 [26][34]

www.leadleo.com 头豹市场研究| 2024/04 电力设备制造系列： 可控核聚变设备：人类终极能源，资 本争相涌入 2024 Global Controlled nuclear fusion Industry research report 2024年全球制御核融合研究レポート 报告标签：核聚变、核能、核反应、反应堆 撰写人：马天奇 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性文件 （在报告中另行标明出处者除外）。未经头豹研究院事先书面许可，任何人不得以任何方式擅自复制、再 造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究院保留采取法 律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹"的商号、 商标，头豹研究院无任何前述名称之外的其他分支机构，也未授权或聘用其他任何第三方代表头豹研究院 开展商业活动。 （摘要版） 头豹市场研读 | 2024/05 观点摘要 可控核聚变设备行业正处于技术突破和商业化应用的关键阶段，尽管面临高温等离子体稳定 控制、材料耐高温与辐射性能提升以及能量输出效 ...

2024年 头豹行业词条报告 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度 机密性文件（在报告中另行标明出处者除外）。未经头豹研究院事先书面许可，任何人不得以 任何方式擅自复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的 行为发生，头豹研究院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有 商业活动均使用"头豹研究院"或"头豹"的商号、商标，头豹研究院无任何前述名称之外的 其他分支机构，也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 Copyright © 2024 头豹 Leadleo.com 产企业积极布局 头豹词条报告系列 "钙DK"同补理念盛行，引导老年骨骼健康产品生 荆婧 · 头豹分析师 2024-08-01 未经平台授权，禁止转载 版权有问题？点此投诉 行业： 制造业/医药制造业/保健及康复食品制造 消费品制造/医疗保健 关键词： 骨质疏松 骨关节炎 钙 氨糖 软骨素 维生素D 维生素K | --- | --- | --- | --- | |------------------------------------- ...

头豹 LeadLeo 2024年 头豹行业词条报告 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度 机密性文件（在报告中另行标明出处者除外）。未经头豹研究院事先书面许可，任何人不得以 任何方式擅自复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的 行为发生，头豹研究院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有 商业活动均使用"头豹研究院"或"头豹"的商号、商标，头豹研究院无任何前述名称之外的 其他分支机构，也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 Copyright © 2024 头豹 Leadleo.com 工业上楼：垂直整合新趋势，驱动产业升级新高度 头豹词条报告系列 陈祖杰 · 共创作者 2024-08-01 未经平台授权，禁止转载 陈 行业： 建筑业/建筑安装业/其他建筑安装业 地产建筑/建筑 版权有问题？点此投诉 | --- | --- | --- | --- | |-------------------------|--------------------------|------------------- ...

中国压力计行业市场规模测算逻辑 模型 头豹词条报告系列 张宇彤 发布日期：2024/08/16 压力计行业规模 1. 压力计行业规模 (结论图) P314. 网络通信市场规模 P16 2. 压力计行业规模 P4 15. 网络通信领域压力计规模 P17 3. 中国传统燃油汽车销售量 P5 16. 电子类消费产品市场规模 P18 4. 压力计渗透率 P6 17. 电子类消费产品压力计规模 P19 5. 中国传统燃油汽车保有量 P7 18. 溯源信息链接引用 P20 6. 中国新能源汽车销售量 P8 19. 溯源信息链接引用 P21 7. 压力计 P9 20. 溯源信息链接引用 P22 8. 中国新能源汽车保有量 P10 21. 法律声明 P23 9. 汽车电子领域压力计规模 P11 22. 头豹研究院简介 P24 10. 中国医疗电子市场规模 P12 23. 头豹词条介绍 P25 11. 医疗电子领域压力计规模 P13 24. 头豹词条报告 P26 12. 工业控制市场规模 P14 13. 工业控制领域压力计规模 P15 ሙ 1. 压力计行业规模（结论图） 中国传统燃油汽车销 售量 A 中国医疗电子市场规 医疗电 ...